Jul 15 2015
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, today announced that it will be presenting preclinical data on its two lead anti-infective product candidates, MAT2203 and MAT2501, at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific meeting Sept. 17 - 21 in San Diego.
Matinas BioPharma will present preclinical data on MAT2203, the Company's novel lipid-crystal nano-particle delivered formulation of Amphotericin B, from an abstract entitled, "Oral Dosing of Encochleated Amphotericin B (CAmB): Rapid Drug Targeting to Infected Tissues in Mice with Systemic Candidiasis," on Friday, Sept. 18, noon - 2 p.m. in a poster session focused on Pharmacokinetics/Pharmacodynamics of New Drugs in Development. MAT2203, an oral broad spectrum fungicidal agent, is expected to enter Phase 2a clinical studies for the treatment of mucocutaneous fungal infections in collaboration with the National Institutes of Health/National Institute of Allergy and Infectious Disease (NIH/NIAID) this year.
Additionally, preclinical data on Matinas BioPharma's early-stage development program to treat gram-negative bacterial infections, MAT2501, will also be presented from a study entitled, "Oral Encochleated Amikacin Demonstrates Activity In Vivo and In Vitro in Biofilm Models of Mycobacterium avium," on Saturday, Sept. 19, 11 a.m. - 1 p.m., in a poster session on pneumonia. MAT2501 is a gram-negative aminoglycoside antibiotic delivered in the Company's proprietary lipid-crystal nano-particle cochleate formulation. Matinas BioPharma anticipates filing an investigational new drug (IND) application with the U.S. Food and Drug Administration for MAT2501 this year.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company with a principal focus on identifying and developing novel and targeted pharmaceutical products for the treatment of various infectious diseases, with additional programs developing therapies to treat cardiovascular and metabolic conditions. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas BioPharma is focused on creating highly differentiated, safe and efficacious therapies utilizing its expertise in drug formulation and development in order to address significant unmet medical needs. The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+